Single-use Bioreactors Market Analysis

Single-use Bioreactors Market Analysis

To get key market trends

  Download Free Sample

The market by product is categorized into stirred tank single-use bioreactors, wave-mixed single-use bioreactors, bubble column single-use bioreactors, and others. The stirred tank single-use bioreactors segment garnered USD 1.5 billion revenue size in the year 2022.
 

• Single-use bioreactors eliminate the need for cleaning and sterilization between batches, significantly reducing the risk of cross-contamination between different products or batches. This is crucial in the production of biopharmaceuticals, where even trace amounts of contaminants can compromise the entire batch.
   
• Moreover, traditional stainless-steel bioreactors require significant capital investment and operating costs for cleaning, sterilization, and maintenance. Single-use bioreactors eliminate these costs associated with cleaning and validation, leading to overall cost savings.
  
   

Based on cell, the single-use bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, other cells. The mammalian cells segment accounted for over 79% business share in 2022. The segment's growth can be attributed to enhanced demand for mammalian cells in the discovery and commercial manufacturing of therapeutic proteins, viral vaccines, and several other biopharmaceuticals, which will drive demand for single-use bioreactors.
 

• Moreover, these cells are widely used to develop tissue analogues for regenerative therapeutics which will further drive the segment share.  
   
• In addition, extensive usage of mammalian cells in the research for various applications coupled with capacity of adding human-like post-translational variations to complex protein therapeutics will drive the segment trends.
   

Based on molecule, the single-use bioreactors market is segmented into monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, other molecules.


The vaccines segment accounted for over 50% revenue share in 2022 and is anticipated to witness highest growth during the forecast period.

• The segment growth is primarily attributable to extensive vaccine development activities owing to sudden upsurge in demand for COVID-19 vaccines. Expansion of vaccination and opening of mass COVID-19 vaccination sites are the factors contributing to the growth of the segment.
   
• Also, the increasing prevalence rate of numerous chronic infectious ailments will boost the research & development activities for vaccine development thereby, stimulating the demand for the single-use bioreactors.
   

Based on usage, the single-use bioreactors market is segmented into developmental, pre-clinical & clinical and commercial production. The developmental, preclinical, and clinical segment is projected to grow at 16.5% CAGR during the forecast period.  
 

• High demand for infectious disease vaccines and drugs has increased the number of preclinical and clinical research activities. Increasing use of single-use bioreactors in preclinical and clinical studies is augmenting its market expansion. Thus, emphasis on speedy FDA approval and improvement in vaccination criteria are the factors responsible for rise in preclinical and clinical studies.
   
• Moreover, the strong presence of biopharmaceutical manufacturers that are highly involved in R&D activities for product innovation will foster the market demand.
   

Thus, growing focus on novel innovation will create lucrative growth opportunities for the market in the foreseeable future.
 

The single-use bioreactors market by end-use is categorized into R&D organizations, biopharma manufacturers, contract manufacturing organizations. Biopharma manufacturers held 45% of industry share in 2022.
 

• Increase in number of biopharmaceutical products in pipeline including antibodies and antibody drug conjugates coupled with rising number of new facilities to meet the production needs is anticipated to augment segment landscape.
   
• Growing adoption of advanced technologies to ease complex manufacturing will stimulate industry demand in upcoming years.
   
• Moreover, single-use bioreactors cater wide applications in development and manufacturing of complex molecules such as proteins and nucleic acids is estimated to drive the segment size.
   

U.S. single-use bioreactors market accounted for USD 795 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline.
 

• Technological advancements coupled with increasing healthcare expenditure on R& D activities are the factors driving the market growth. Increasing incidence of infectious diseases along with rising demand for vaccine production will stimulate the use of single-use bioreactors.
   
• Major players in the pharmaceutical industry are focusing on expanding production capacity and developing new therapies including gene therapy and recombinant protein therapy, thereby creating new opportunities for the U.S. market demand.
   
• Further, contract manufacturing organizations (CMOs) are being used for most of the processes in the healthcare industry as several players from emerging countries are entering the market. Companies from the U.S. are establishing operations in the emerging countries such as India, South Korea, Singapore, and China.